Bilayer Therapeutics™, Inc. was formed to develop drugs to treat diseases of the colon, first, BL-010, a bile acid-based, first-in-class therapeutic for constipation and then other drugs for metabolic disorder (obesity, diabetes), hepatic encephalopathy, etc. via a proprietary bilayer tablet technology. We are looking to raise an additional seed financing of $2M (now) followed by a Series A of $15M (early 2023).